唐氏综合征与常染色体显性阿尔茨海默病个体淀粉样蛋白负荷比较:横断面研究
该横断面研究纳入ABC-DS研究中192例唐氏综合征患者及33例同胞对照,以及DIAN研究中265例常染色体显性阿尔茨海默病突变携带者及169例非携带者家族对照,比较淀粉样PET负荷。无症状及有症状两组间全局淀粉样负荷均无显著差异,但突变携带者淀粉样沉积显著更早出现,唐氏综合征患者内侧枕区免受累及。
要点
- 唐氏综合征与常染色体显性阿尔茨海默病症状性及无症状阶段全局淀粉样PET负荷均无显著差异。
- 突变携带者淀粉样沉积显著早于唐氏综合征患者出现,主要由PSEN1突变驱动。
- 唐氏综合征患者早期淀粉样沉积见于纹状体和皮层,但内侧枕区免受累及。
核心结论
- 尽管存在微小差异,常染色体显性阿尔茨海默病与唐氏综合征患者的淀粉样PET改变相似,强烈支持唐氏综合征个体早期存在淀粉样蛋白失调。
- 年龄至少35岁的唐氏综合征个体可能从早期干预中获益,并值得未来纳入临床试验,尤其考虑到唐氏综合征发病率相对较高。
研究设计与样本
- 横断面研究,纳入ABC-DS研究首次数据发布(2020年1月)中年龄≥25岁且完成MRI和淀粉样PET的唐氏综合征患者及同胞对照。
- 纳入DIAN研究数据冻结(2020年12月)时年龄25-73岁且完成MRI和淀粉样PET的常染色体显性阿尔茨海默病突变携带者及非携带者家族对照,两研究对照合并为单一组。
- 共纳入192例唐氏综合征患者、33例同胞对照、265例突变携带者及169例非携带者家族对照。
主要发现
- 突变携带者(n=216)中PET淀粉样蛋白centiloid与脑脊液Aβ42/40呈负相关(r=-0.565,p<0.0001),唐氏综合征患者(n=32)中亦呈负相关(r=-0.801,p<0.0001)。
- 无症状唐氏综合征患者全局淀粉样PET负荷(均值18.80 centiloid,SD 28.33)与无症状突变携带者(24.61 centiloid,SD 30.27)无差异(p=0.11)。
- 有症状唐氏综合征患者全局淀粉样PET负荷(77.25 centiloid,SD 41.76)与有症状突变携带者(69.15 centiloid,SD 51.10)无差异(p=0.34)。
- APOE ɛ4状态和性别对全局淀粉样PET沉积无影响。
- 突变携带者淀粉样沉积显著更早于唐氏综合征参与者出现(估计症状发作年数-23.0 vs -17.5;p=0.0002),PSEN1突变主要驱动该差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Important insights into the early pathogenesis of Alzheimer's disease can be provided by studies of autosomal dominant Alzheimer's disease and Down syndrome. However, it is unclear whether the timing and spatial distribution of amyloid accumulation differs between people with autosomal dominant Alzheimer's disease and those with Down syndrome. We aimed to directly compare amyloid changes between these two groups of people. METHODS: In this cross-sectional study, we included participants (aged ≥25 years) with Down syndrome and sibling controls who had MRI and amyloid PET scans in the first data release (January, 2020) of the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. We also included carriers of autosomal dominant Alzheimer's disease genetic mutations and non-carrier familial controls who were within a similar age range to ABC-DS participants (25-73 years) and had MRI and amyloid PET scans at the time of a data freeze (December, 2020) of the Dominantly Inherited Alzheimer Network (DIAN) study. Controls from the two studies were combined into a single group. All DIAN study participants had genetic testing to determine PSEN1, PSEN2, or APP mutation status. APOE genotype was determined from blood samples. CSF samples were collected in a subset of ABC-DS and DIAN participants and the ratio of amyloid β42 (Aβ42) to Aβ40 (Aβ42/40) was measured to evaluate its Spearman's correlation with amyloid PET. Global PET amyloid burden was compared with regards to cognitive status, APOE ɛ4 status, sex, age, and estimated years to symptom onset. We further analysed amyloid PET deposition by autosomal dominant mutation type. We also assessed regional patterns of amyloid accumulation by estimated number of years to symptom onset. Within a subset of participants the relationship between amyloid PET and CSF Aβ42/40 was evaluated. FINDINGS: 192 individuals with Down syndrome and 33 sibling controls from the ABC-DS study and 265 carriers of autosomal dominant Alzheimer's disease mutations and 169 non-carrier familial controls from the DIAN study were included in our analyses. PET amyloid centiloid and CSF Aβ42/40 were negatively correlated in carriers of autosomal dominant Alzheimer's disease mutations (n=216; r=-0·565; p<0·0001) and in people with Down syndrome (n=32; r=-0·801; p<0·0001). There was no difference in global PET amyloid burden between asymptomatic people with Down syndrome (mean 18·80 centiloids [SD 28·33]) versus asymptomatic mutation carriers (24·61 centiloids [30·27]; p=0·11) and between symptomatic people with Down syndrome (77·25 centiloids [41·76]) versus symptomatic mutation carriers (69·15 centiloids [51·10]; p=0·34). APOE ɛ4 status and sex had no effect on global amyloid PET deposition. Amyloid deposition was elevated significantly earlier in mutation carriers than in participants with Down syndrome (estimated years to symptom onset -23·0 vs -17·5; p=0·0002). PSEN1 mutations primarily drove this difference. Early amyloid accumulation occurred in striatal and cortical regions for both mutation carriers (n=265) and people with Down syndrome (n=128). Although mutation carriers had widespread amyloid accumulation in all cortical regions, the medial occipital regions were spared in people with Down syndrome. INTERPRETATION: Despite minor differences, amyloid PET changes were similar between people with autosomal dominant Alzheimer's disease versus Down syndrome and strongly supported early amyloid dysregulation in individuals with Down syndrome. Individuals with Down syndrome aged at least 35 years might benefit from early intervention and warrant future inclusion in clinical trials, particularly given the relatively high incidence of Down syndrome. FUNDING: The National Institute on Aging, Riney and Brennan Funds, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the German Center for Neurodegenerative Diseases, and the Japan Agency for Medical Research and Development.
引用
- Boerwinkle AH, Gordon BA, Wisch J, et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurol. 2023. PMID: 36517172. doi:10.1016/S1474-4422(22)00408-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。